Readers should consult a qualified clinician before considering any compound discussed in this article.
A clinical researcher who has tracked GLP-1 prescribing patterns for five years recently described a patient case that stuck with him. A 54-year-old woman with obesity but no diabetes started semaglutide for weight loss. Within eight weeks, her nightly wine habit dropped from three glasses to one. She also reported feeling colder, more fatigued, and less motivated to exercise. Her resting metabolic rate, measured by indirect calorimetry, had fallen 9 percent. The researcher wondered if the alcohol reduction itself, not just the calorie deficit, was driving the metabolic slowdown.
That question frames a growing area of inquiry. Semaglutide and tirzepatide are now widely prescribed for weight loss. A 2022 review in Frontiers in Endocrinology noted that GLP-1 receptor agonists reduce alcohol intake in rodent models and some human trials. A 2023 case series in Diabetes, Obesity and Metabolism described reduced alcohol craving in patients taking semaglutide for obesity. But the metabolic cost of drinking less is rarely discussed. Alcohol contributes roughly 7 calories per gram, and chronic drinkers often have elevated basal metabolic rates due to alcohol-induced thermogenesis and sympathetic activation. Remove alcohol, and the body may downshift.
MOTS-c, a mitochondrial-derived peptide encoded in the 12S rRNA region of mitochondrial DNA, has drawn attention for its effects on metabolic flexibility. A 2019 study in Cell Metabolism by Lee and colleagues showed MOTS-c improved insulin sensitivity and increased energy expenditure in mice fed a high-fat diet. A 2021 paper in Nature Communications found MOTS-c levels decline with age and correlate with reduced mitochondrial function. Could MOTS-c blunt the metabolic adaptation that follows alcohol cessation in patients on semaglutide? The researcher offered a cautious view.
Q1: What does the current evidence say about semaglutide reducing alcohol craving in non-diabetic obese patients?
"The strongest human data comes from a 2022 randomized trial published in JAMA Psychiatry. Klausen and colleagues gave 127 patients with alcohol use disorder either semaglutide or placebo for 26 weeks. The semaglutide group reported fewer heavy drinking days and lower craving scores. But that trial excluded people with obesity and diabetes. For non-diabetic obese patients, the evidence is thinner. A 2023 observational study in Obesity followed 84 patients on semaglutide for weight loss. About 40 percent reported a spontaneous reduction in alcohol intake. The mechanism likely involves GLP-1 receptors in the nucleus accumbens and ventral tegmental area, which modulate reward signaling."
He paused. "The problem is that most obesity trials don't measure alcohol consumption as an endpoint. So we're left with anecdotes and small case series. The 2023 case series I mentioned earlier is instructive. Six patients, all non-diabetic, all on semaglutide for obesity. Five reduced alcohol intake by at least half within three months. But four of those five also showed a drop in resting energy expenditure beyond what calorie restriction alone would predict."
Q2: How significant is the metabolic slowdown after reducing alcohol intake in these patients?
"It's underappreciated. Alcohol is a macronutrient that the body metabolizes inefficiently. Chronic drinkers often have higher resting metabolic rates because alcohol induces futile cycling in the liver and increases sympathetic tone. When alcohol stops, that thermogenic effect disappears. A 2018 study in Alcoholism: Clinical and Experimental Research found that abstinent alcoholics had resting metabolic rates 5 to 8 percent lower than matched controls, even after accounting for body composition. Now layer on semaglutide, which itself reduces energy expenditure through weight loss and possibly direct central effects. The combination could be additive."
He leaned forward. "In the patient I described, her 9 percent drop in metabolic rate translated to about 140 fewer calories burned per day at rest. That's enough to stall weight loss or even cause regain if she doesn't adjust intake. And she felt it. Cold intolerance, fatigue, low motivation. Those are classic signs of a downregulated thyroid axis and reduced sympathetic outflow."
Q3: What is MOTS-c, and why might it help prevent this metabolic adaptation?
"MOTS-c is a 16-amino-acid peptide produced from mitochondrial DNA. It acts on the folate cycle and AMPK pathway to improve glucose uptake and fatty acid oxidation. In a 2019 paper in Cell Metabolism, Lee and colleagues showed that MOTS-c injections prevented diet-induced obesity in mice and increased their energy expenditure. A 2020 study in Peptides by Chang and colleagues found MOTS-c improved mitochondrial biogenesis in skeletal muscle of aged mice. The idea is that MOTS-c could counteract the mitochondrial downshift that occurs when alcohol is removed and semaglutide is on board."
He shrugged. "But human data is almost nonexistent. There are a few small trials in metabolic syndrome. A 2021 pilot study in Journal of Translational Medicine gave MOTS-c to 20 obese men for four weeks. They saw modest improvements in insulin sensitivity and a small increase in resting energy expenditure. No trial has combined MOTS-c with a GLP-1 agonist or looked at alcohol cessation. So we're extrapolating from animal models and first principles."
Q4: Are there other peptides, like tesamorelin or AOD-9604, that could serve a similar role?
"Tesamorelin is a growth hormone-releasing hormone analog. It's FDA-approved for HIV lipodystrophy. It reduces visceral fat and can increase lean mass. A 2023 study in Obesity found tesamorelin preserved resting energy expenditure during caloric restriction in obese adults. That's relevant because semaglutide often causes loss of lean mass, which further lowers metabolic rate. But tesamorelin doesn't directly address mitochondrial function or alcohol-related thermogenesis. AOD-9604 is a fragment of human growth hormone that has lipolytic effects. A 2022 review in Endocrine Reviews noted AOD-9604 may reduce fat mass without affecting blood sugar. But again, no data on alcohol cessation."
He tapped the table. "Hexarelin is a ghrelin receptor agonist. It increases growth hormone release and can improve cardiac function. But ghrelin also stimulates appetite and alcohol seeking in some models. So hexarelin might be counterproductive in this context. MOTS-c is more targeted to mitochondrial energetics, which is where the metabolic slowdown originates."
Q5: What would a clinical trial of semaglutide plus MOTS-c for alcohol reduction and metabolic preservation look like?
"You'd want a three-arm design. Semaglutide alone, semaglutide plus MOTS-c, and placebo. Non-diabetic obese patients with risky alcohol use, defined by AUDIT scores. Primary endpoint: change in heavy drinking days at 24 weeks. Secondary endpoints: resting metabolic rate by indirect calorimetry, body composition by DEXA, mitochondrial function by muscle biopsy or serum markers like FGF21 and GDF15. You'd need to control for calorie intake, which is hard. But if MOTS-c could maintain energy expenditure while semaglutide reduces alcohol craving, that would be a compelling combination."
He smiled. "The challenge is funding. MOTS-c is a research peptide, not a blockbuster drug. No pharma company owns it. So the trial would likely come from an academic center or a private research group. And the regulatory path is murky. MOTS-c is not FDA-approved for any indication. Investigators would need an IND. But the scientific rationale is solid."
What the researcher is watching next
He mentioned a 2024 preprint from a group in Denmark that combined semaglutide with a mitochondrial uncoupler in mice. The combination prevented weight regain after semaglutide cessation. "That's the same logic. Keep the metabolic rate up while the GLP-1 does its work on appetite and reward. MOTS-c is a cleaner candidate because it's endogenous and has a good safety profile in early human studies."
He also pointed to ongoing work on GLP-1 and alcohol use disorder. A 2023 trial registered on ClinicalTrials.gov is testing semaglutide in patients with both obesity and alcohol use disorder. "If that trial shows a real effect on drinking, the metabolic question becomes urgent. We can't just accept a 9 percent drop in resting metabolic rate as the price of sobriety. Patients will stop the drug. They'll regain weight. They'll return to alcohol. We need a countermeasure."
The researcher's final observation was clinical. "In my practice, I ask every patient on semaglutide about alcohol. Most don't volunteer it. When I tell them the drug may reduce their craving, they're surprised. Then I ask about energy, cold tolerance, motivation. That's where the metabolic slowdown shows up. If MOTS-c or another mitochondrial peptide can blunt that, we might keep patients on therapy longer and improve their quality of life. But we need data, not anecdotes."
For readers tracking the GLP-1 market, the intersection of alcohol reduction and metabolic preservation is a niche worth watching. The semaglutide alcohol reduction trial already raised questions about muscle and sleep. The tirzepatide and hexarelin stack discussion touches on lean mass preservation. And the semaglutide and bone health debate highlights the broader metabolic risks of rapid weight loss. MOTS-c remains a research chemical, not a clinical tool. But the hypothesis is testable, and the need is growing.